Jinhui Xue

Jinhui Xue

Auto-generated profile, based on publicly available information

Jinhui Xue

Department of Clinical Research, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong 510060, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2023 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
YMYuxiang Ma
Yuxiang Ma
JXJinhui Xue
Jinhui Xue
YZYuanyuan Zhao
Yuanyuan Zhao
YZYang Zhang
Yang Zhang
YHYan Huang
Yan Huang
HZHongyun Zhao
Hongyun Zhao
Background KN046 is a novel bispecific antibody targeting programmed death ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4). This multicenter phase I trial investigated the safety, tolerability, pharmacokinetics (PK), and efficacy of KN046 in patients with advanced solid tumors. Methods Patients who failed standard treatment were included. KN046 was administered at doses of 1, 3, and 5 mg/kg every 2 weeks (Q2W), 5 mg/kg every 3 weeks (Q3W), and 300 mg Q3W based on the modified toxicity probability interval method in the dose-escalation phase; the recommended dose was used in the expansion phase. Primary objectives were maximum tolerated dose (MTD) and recommended phase II dose (RP2D) in escalation and preliminary efficacy in expansion. Secondary objectives included PK, pharmacodynamics, safety, and tolerability of KN046. We also explored biomarkers based on PD-L1 expression, multiplex immunofluorescence (mIF) staining, and RNAseq-derived nCounter platform. Results Totally, 100 eligible patients were enrolled, including 59 with nasopharyngeal carcinoma (NPC), 36 with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC), and those with other advanced solid tumors. The most common treatment-related adverse events (TRAEs) were rash (33.0%), pruritus (31.0%), and fatigue (20.0%). Grade ≥3 TRAEs were observed in 14.0% of participants. No dose-limiting toxicity occurred in the dose-escalation phase, and the MTD was not reached. The RP2D was determined as 5 mg/kg Q2W according to the pharmacokinetic–pharmacodynamic model, the preliminary exposure–response analysis, and the overall safety profile. Among 88 efficacy-evaluable participants, the objective response rate (ORR) was 12.5%, and the median duration of response was 16.6 months. In the NPC subgroup, the ORR was 15.4%, and the median overall survival (OS) was 24.7 (95% CI 16.3 to not estimable) months. In the EGFR-mutant NSCLC subgroup, the ORR was 6.3%. mIF analysis results showed patients with high CD8 expression showed longer median OS (27.1 vs 9.2 months, p=0.02); better prognosis was observed in patients with high CD8 and PD-L1 expression. Conclusions KN046 was well tolerated and showed promising antitumor efficacy in advanced solid tumors, especially in patients with NPC. The combination of both CD8 and PD-L1 expression improved the prediction of KN046 response. Trial registration numbers NCT03733951 .

21 April 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
JXJinhui Xue
Jinhui Xue
YMYuxiang Ma
Yuxiang Ma
YZYuanyuan Zhao
Yuanyuan Zhao
YWYongsheng Wang
Yongsheng Wang
WHWei Hong
Wei Hong
HZHongyun Zhao
Hongyun Zhao
Purpose: Izalontamab (SI-B001) is a novel EGFR×HER3 bispecific antibody. This first-in-human phase I study presents the safety and pharmacokinetics of izalontamab. Patients and Methods: Previously treated patients with locally advanced or metastatic epithelial tumors were enrolled in the dose-escalation or dose-expansion phases. The dose-escalation phase consisted of an accelerated titration and a “3 + 3” design with nine dose levels from 0.4 to 28.0 mg/kg. The dose-expansion phase included five dose levels from 6.0 to 21.0 mg/kg. Izalontamab was administered intravenously weekly or every 2 weeks in a 4-week cycle. Available pretreatment specimens were obtained to explore the relationship between EGFR/HER3 expression and efficacy. Results: Sixty patients were enrolled. Among the 60 enrolled patients, 49 had non–small cell lung cancer (NSCLC), 6 had nasopharyngeal cancer, 3 had head and neck cancer squamous cell carcinoma, and 2 had other types of cancer. The most common treatment-related adverse events were rash (42%), paronychia (25%), and infusion-related reactions (23%). No drug-related death occurred. Izalontamab displayed a nonlinear pharmacokinetic behavior, and clearance at steady state seemed to be approaching a dose-independent value at 6 mg/kg and above. The best response included two confirmed partial responses in patients with NSCLC and head and neck cancer squamous cell carcinoma; 18 patients had stable disease, including NSCLC (n = 17) and colorectal cancer (n = 1). The recommended phase II dose for izalontamab was determined as 9 to 16 mg/kg weekly. Conclusions: Izalontamab was well tolerated and demonstrated preliminary antitumor activity in patients with locally advanced or metastatic epithelial tumors, supporting it as a promising therapeutic candidate for combination therapies, with a phase III study currently underway.

2 June 2024 in Medcomm
Verified
Journal Article
Open access
ZZZhonghan Zhang
Zhonghan Zhang
JXJinhui Xue
Jinhui Xue
YYYunpeng Yang
Yunpeng Yang
WFWenfeng Fang
Wenfeng Fang
YHYan Huang
Yan Huang
HZHongyun Zhao
Hongyun Zhao
TP53 comutation is related to poor prognosis of non‐small cell lung cancer. However, there is limited study focusing on the structural influence of TP53 mutation on third‐generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) treatment. We retrospectively analyzed the clinical and molecular data of patients treated with third‐generation EGFR‐TKIs in two independent cohorts. A total of 117 patients from the Sun Yat‐sen University Cancer Center (SYSUCC) and 141 patients from the American Association for Cancer Research Project GENIE database were included. In the SYSUCC cohort, TP53 comutations were found in 59 patients (50.4%) and were associated with poor median progress‐free survival (mPFS) and median overall survival (mOS). The additional subtype analysis found that TP53 mutation in the alpha‐helix region had shorter mOS compared with those with TP53 mutations in other regions in the SYSUCC cohort (mOS, 12.2 vs. 21.7 months; p = 0.027). Similar findings were confirmed in the GENIE cohort. Specifically, the presence of TP53 mutation in the alpha‐helix region was an independent negative predictive factor for PFS [hazard ratio (HR) 2.05(1.01–4.18), p = 0.048] and OS [HR 3.62(1.60–8.17), p = 0.002] in the SYSUCC cohort. TP53 mutation in alpha‐helix region was related to inferior clinical outcomes in patients treated with third‐generation EGFR‐TKIs.

24 March 2026 in Cancer Discovery
Verified
Journal Article
Closed access
JZJiani Zheng
Jiani Zheng
SZShen Zhao
Shen Zhao
JZJianhua Zhan
Jianhua Zhan
WZWeitao Zhuang
Weitao Zhuang
MCMaojian Chen
Maojian Chen
JLJing Li
Jing Li
While epidermal growth factor receptor (EGFR) fusions in non-small cell lung cancer (NSCLC) typically show sensitivity to tyrosine kinase inhibitors (TKIs), we identified an EGFR-SHC1 fusion subtype that exhibits intrinsic resistance to EGFR-TKI monotherapy through a dual activation mechanism in the preclinical and clinical setting. EGFR-SHC1 fusion protein comprises of N-terminal EGFR and C-terminal SHC1. We demonstrated that EGFR-SHC1 simultaneously activates the EGFR kinase domain (KD) and SRC-mediated phosphorylation of the SHC1 fusion partner, thereby driving ERK/AKT pathway activation and tumorigenesis independent of KD inhibition. Structural modeling coupled with domain-specific mutagenesis revealed that SHC1 phosphorylation establishes a kinase-independent bypass mechanism. Notably, dual-targeted inhibition using afatinib (EGFR-TKI) in combination with dasatinib (SRC-TKI) induced marked tumor regression in a TKI-refractory NSCLC patient with EGFR-SHC1. This study illustrates a cooperative oncogenesis between kinase and scaffold protein in fusions, providing a clinically actionable strategy for overcoming TKI resistance in patients with these oncogenic fusions.

3 August 2026
Verified
Other
Open access
PDF file
JZJiani Zheng
Jiani Zheng
SZShen Zhao
Shen Zhao
JZJianhua Zhan
Jianhua Zhan
WZWeitao Zhuang
Weitao Zhuang
MCMaojian Chen
Maojian Chen
JLJing Li
Jing Li
Supplementary Figure S3 shows that both the N-terminal EGFR kinase domain and the C-terminal SHC1 phosphorylation sites contribute to the oncogenic properties of EGFR-SHC1, including analyses of SHC1 phosphorylation in response to EGF stimulation, TKI sensitivity in Ba/F3 cells, and functional assessments via soft agar colony formation and IL-3-independent proliferation assays using various EGFR-SHC1 mutants. It also includes immunoblotting validation of protein expression and downstream signaling in cells expressing EGFR-RAD51 and EGFR-SHC1 variants.

3 August 2026
Verified
Other
Open access
PDF file
JZJiani Zheng
Jiani Zheng
SZShen Zhao
Shen Zhao
JZJianhua Zhan
Jianhua Zhan
WZWeitao Zhuang
Weitao Zhuang
MCMaojian Chen
Maojian Chen
JLJing Li
Jing Li
Supplementary Table S3 shows that oligonucleotides used in this study.